<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to evaluate the effects of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> and <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> alone and in combination in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> associated with combined <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 216 patients with total cholesterol &gt;/=200 mg/dl (&gt;/=5.17 mmol/l) and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> &gt;/=200 and &lt;800 mg/dl (&gt;/=2.26 and &lt;9.03 mmol/l) were randomised to one of two placebo groups, <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 5 mg or <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 10 mg for 6 weeks (fixed-dose phase) </plain></SENT>
<SENT sid="2" pm="."><plain>During the subsequent 18-week dose-titration phase, one placebo group received titrated <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 10, 20 and 40 mg (placebo/<z:chebi fb="0" ids="38545">rosuvastatin</z:chebi>); one placebo group received titrated <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> 67 mg once, twice and three times daily (placebo/<z:chebi fb="0" ids="5001">fenofibrate</z:chebi>); and patients receiving 5 or 10 mg <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> received titrated <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> as above (<z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 5mg/fenofibrate and <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 10 mg/fenofibrate groups) </plain></SENT>
<SENT sid="3" pm="."><plain>Doses were increased at 6-week intervals if <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) cholesterol remained &gt;50 mg/dl (&gt;1.3 mmol/l) </plain></SENT>
<SENT sid="4" pm="."><plain>At 24 weeks, the placebo/<z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> group and placebo per <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> group had <z:chebi fb="0" ids="17855">triglyceride</z:chebi> reductions of 30.3% versus 33.6%, respectively (P = NS), and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> was reduced by 46.7% in the <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> group and increased by 0.7% in the <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> group (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="0" ids="17855">triglyceride</z:chebi> reduction in the <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 10 mg/fenofibrate group (47.1%) was significantly greater than in the placebo/<z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> group (P = 0.001), with no significant differences in other <z:chebi fb="23" ids="18059">lipid</z:chebi> measures found between these two groups </plain></SENT>
<SENT sid="6" pm="."><plain>No significant differences in effect on <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) were observed among treatment groups </plain></SENT>
<SENT sid="7" pm="."><plain>In the fixed-dose phase, <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 5 and 10 mg reduced <z:chebi fb="4" ids="17855">triglycerides</z:chebi> by 24.5 and 29.5%, respectively, and decreased <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> by 40.7 and 45.8%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> treatments were well tolerated </plain></SENT>
<SENT sid="9" pm="."><plain>These results indicated that <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> produces marked reductions in <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> when used alone or in combination with <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients with <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">elevated cholesterol</z:e> and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels and may constitute a valuable treatment option in the diabetic population </plain></SENT>
</text></document>